RAPP Rapport Therapeutics, Inc. Insider Trading

10% owner Third Rock Ventures V sells 133,618 shares for $5.4M; 4th sale at RAPP in 36 months with consistent prior exits well-timed as stock fell after each.

Third Rock Ventures V, a significant 10% beneficial owner, is shedding shares for the fourth time in the past three years—a pattern of repeated exits rather than accumulation. This latest sale occurred at a modest premium to the stock's recent trading range, and the fund's prior three exits at RAPP all proved well-timed, with the stock declining following each one, suggesting disciplined capital allocation. Rapport itself remains unprofitable with mounting quarterly losses, and while the stock has rallied notably in recent months, it still trades below its 52-week high. The fund's consistent exits here—now representing a reduction of over 2% of Third Rock Ventures V's original stake—underscore an institutional perspective: rebalancing a holding in a loss-making biotech rather than conviction-level accumulation typical of insider buyers betting on turnaround momentum.

Third Rock Ventures V (10% owner) sells 276k shares for $11.1M; first exit since well-timed prior sale, but stock up significantly in recent months.

L.P. Third Rock Ventures V, a significant institutional holder with over 10% ownership, divested a modest 4.1% of its stake across two sales in early May. The fund's prior sale at this company was well-timed—shares declined afterward—setting a positive precedent for exit decisions. However, this current sale arrives after the stock has gained substantially over recent months and still trades below its 52-week high, an environment where exits traditionally signal less urgency. The company remains unprofitable with mounting losses, though it generated meaningful quarterly revenue, creating a mixed fundamental backdrop. For a portfolio manager of this scale, modest portfolio rebalancing is routine, though the timing—after significant recent gains—suggests a pragmatic trim rather than alarm about deteriorating fundamentals or imminent business deterioration.

Third Rock Ventures V sold 426,005 shares of RAPP at $40.32 on 2026-04-17 under 10b5-1 plan; holds 6.71M shares post-sale

Third Rock Ventures V, a 10% owner, executed a scheduled sale of 426,005 shares for $17,175,243.59 under a pre-arranged 10b5-1 trading plan. The transaction reduced the fund's holding from 7,135,233 shares to 6,709,228 shares, a 6.0% reduction. Because this sale follows a pre-arranged trading plan rather than a discretionary decision, it does not signal a change in conviction or strategic reassessment by the insider; it reflects a predetermined execution schedule. The fund retains substantial ownership, maintaining a 10% stake post-transaction.

CEO Ceesay Abraham sells 76,420 shares ($2.0M) in 4 transactions under scheduled 10b5-1 plan

Ceesay Abraham, Chief Executive Officer of Rapport Therapeutics (RAPP), executed four separate sales totaling 76,420 shares for $2,011,197.18 on September 17, 2025, under a pre-arranged 10b5-1 trading plan adopted on December 12, 2024. The blended average sale price was $26.32 across transactions priced between $26.30 and $27.04. This disposition reduced his holdings from 122,564 shares to 46,144 shares, a reduction of 62.4% relative to pre-transaction holdings. The scheduled nature of this plan, established months in advance, means the timing and volume were predetermined contractually rather than discretionary decisions made in response to current market conditions or company developments.

Director Paul Steven M purchases 41,666 shares at avg $24.65 in 2 transactions; cluster buy pattern as 2 other insiders bought within 14 days.

Director Paul Steven M executed two open-market purchases totaling 41,666 shares for $1,027,111.29 on 2025-09-12, establishing a new position at a blended average price of $24.65. The stock is currently trading at $24.73, near the transaction price, after a 30-day climb of +68.2% and 90-day surge of +125.8%. This buy occurs within a cluster pattern: 2 other insiders also purchased shares within the past 14 days. The company reported negative net income of $-26,732,000.00 over its most recent full fiscal year and carries a market cap of $902.6M. The coordinated accumulation by multiple insiders amid unprofitability and recent sharp price appreciation warrants investor attention to both the motivation behind these concurrent transactions and the company's cash burn trajectory.

Director Huber Reid M buys 20,400 RAPP shares at $24.48; cluster of 3 insiders buying within 14 days as stock rallies +68.2% in 30 days

Director Huber Reid M purchased 20,400 shares at $24.48, establishing an initial position of 20,400 shares. The transaction is part of a cluster buy pattern with 2 other insiders purchasing within the past 14 days. The stock has risen sharply (+68.2% over 30 days, +125.8% over 90 days) from a 52-week low of $7.15, though it remains 21.4% below its 52-week high of $31.47. The company reported a negative net income of $-26,732,000.00 for its most recent full fiscal year, so management is deploying capital to acquire equity stakes in an unprofitable business during a significant rally phase. The multi-insider purchase pattern during strong upward momentum, combined with the company's unprofitable fundamentals, warrants observation of whether this represents confidence in a turnaround or positioning ahead of potential announcements.

Director Wendy B. Young buys 3,500 RAPP shares at $22.60; holdings rise 58.3% to 9,500 shares

Director Wendy B. Young purchased 3,500 shares at $22.60 on 2025-09-11, increasing her stake by 58.3% to 9,500 shares total. This open-market buy occurs at a price 2.6% below the current market price of $23.20, and 30.3% below the stock's 52-week high of $31.47. Notably, her prior buy at RAPP on 2025-03-12 exhibited strong 90-day performance (+28.9%), aligning with a perfect track record pattern on RAPP (1 of 1 prior buys well-timed at the 90-day mark). However, the company remains unprofitable with a full-year net income of $-26,732,000.00, and the stock has appreciated 49.3% over the past 30 days and 107.3% over 90 days — dynamics that context the timing and scale of this incremental accumulation within an already volatile trading environment.

Director Wendy B. Young buys 6,000 shares of RAPP at $10.21 as stock declines 65.7% from 52-week high.

Director Wendy B. Young purchased 6,000 shares of Rapport Therapeutics at $10.21 on 2025-03-12, establishing her first position in the company. The purchase occurs against a backdrop of significant downward momentum: the stock trades at $10.02, representing a -65.7% decline from its 52-week high of $29.23 and a -36.3% drop over the preceding 30 days. The company reported a full-year net income of $-17,537,000.00, indicating ongoing unprofitability. An insider director opening a position near current lows while the company remains unprofitable presents a mixed signal—the acquisition of equity stake during a depressed market period for the stock, coupled with substantial losses, warrants close monitoring of the company's path to profitability and near-term catalysts.

CFO Ignelzi bought 10.0K shares in 2 purchases for $100,988.00 as RAPP down 65.7% from 52-week high

Ignelzi, the Chief Financial Officer of Rapport Therapeutics, made 2 separate purchases totaling 10,000 shares for $100,988.00, bringing his post-transaction holdings from zero to 10,000 shares. The purchases occurred at $10.10 and $9.98 per share on consecutive trading days (March 12-13, 2025), during a period when the stock has declined 65.7% from its 52-week high of $29.23 and 36.3% over the prior 30 days. The company reported a net loss of $17,537,000.00 for its most recent full fiscal year, establishing an unprofitable operating backdrop. An incoming CFO's initial equity purchase—particularly at this scale and timing relative to sharp recent declines—merits scrutiny regarding both his assessment of intrinsic value and any information asymmetries he may possess.

Director James Healy purchases 44,032 shares at $23.30–$26.06 in 12 transactions totaling $1.1M at recently-listed RAPP

James Healy, a director at Rapport Therapeutics, executed 12 separate purchases on 2024-07-01, acquiring 44,032 shares totaling $1,079,575.36 at prices ranging from $23.08 to $26.06, with a blended average of $24.52. This substantial commitment—representing a net addition to his holdings from a negative position to 40,851 shares—occurred just 18 trading days after the company's recent listing. The multi-tranche structure and rapid execution suggest a deliberate accumulation rather than opportunistic activity. With the stock currently trading at $23.30 as of 2024-07-03, the director's purchase prices span slightly above and below the current level, positioning his position during RAPP's nascent public trading phase.